Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 (2017)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- Subjects: NEOPLASIAS MAMÁRIAS; PROGNÓSTICO; SOBREVIVÊNCIA LIVRE DE DOENÇA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Annals of oncology
- ISSN: 0923-7534
- Volume/Número/Paginação/Ano: v. 28, suppl.5, 2017
- Conference titles: 42nd European-Society-for-Medical-Oncology Congress (ESMO)
-
ABNT
BACHELOT, T et al. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://observatorio.fm.usp.br/handle/OPI/25260. Acesso em: 15 fev. 2026. , 2017 -
APA
Bachelot, T., Royce, M., Villanueva, C., Cruz, F. M., Hegg, R., Falkson, C., et al. (2017). Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology. Oxford: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://observatorio.fm.usp.br/handle/OPI/25260 -
NLM
Bachelot T, Royce M, Villanueva C, Cruz FM, Hegg R, Falkson C, Jeong J, Srimuninnimit V, Arce CH, Ridolfi A. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 [Internet]. Annals of oncology. 2017 ; 28[citado 2026 fev. 15 ] Available from: http://observatorio.fm.usp.br/handle/OPI/25260 -
Vancouver
Bachelot T, Royce M, Villanueva C, Cruz FM, Hegg R, Falkson C, Jeong J, Srimuninnimit V, Arce CH, Ridolfi A. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 [Internet]. Annals of oncology. 2017 ; 28[citado 2026 fev. 15 ] Available from: http://observatorio.fm.usp.br/handle/OPI/25260 - Eficacia, tolerabilidade e aceitabilidade do estradiol transdermico no tratamento dos sintomas da menopausa
- Sindrome do climaterio: conceito, importancia e epidemiologia
- Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study
- Câncer da mama: quadro clínico, diagnóstico e estadiamento
- Mastite puerperal
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)
- Galactorreia: sindrome hiperprolactinemica
- Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
